BibTex RIS Cite

VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B

Year 2003, Volume: 16 Issue: 3, 211 - 213, 03.12.2016

Ayça Vitrinel Gülay Çiler Erdag Öznur Kılıç Tuba Giray Vural Kartal Şinasi Yaman Yasemin Akın

Abstract

Three children under 5 years of age with visceral leishmaniasis, responded dramatically to a short course of liposomal amphotericin B (L-AmB) and are presented and discussed in the view of literature.
Key Words: Leishmaniasis, Liposomal amphotericin B

References

  • I. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med tlyg 1992; 46 : 296-306.
  • Croft SL, Davidson RM, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother 1991 ; 28 : 111-118.
  • Meyrhoff A.U.S. Pood and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999 ;28 : 42-48.
  • Qradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995 ; 73 :191-197.
  • Thakur CP, Kumar M, Kumar P, Mishra BM, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomized study. Br Med J 1988 ; 296 : 1557-1561.
  • Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez-Berestein Q. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 1986 ; 30 : 847-851.
  • Davidson RM, Croft SL, Scott AO, Maini M, Moody AH, Bryceson AOM. Liposomal amphotericin B in drug resistant visceral leishmaniasis. Lancet 1991 ; 337 : 1061- 1062
  • Davidson RM, Di Marti no L, Oradoni R, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi centre trial. Quart J Med 1994 ; 87 : 75-81.
  • Castagnola E, Davidson RM, Fiore P, et al. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis. Trans Roy Soc Trop Med Hyg 1996 ; 90 : 31 7-318
  • Giacchino R, Giambartolome G, Tasso L, et al. Treatment with liposomal amphotericin B of a child affected with drug-resistant visceral leishmaniasis. Trans Roy Soc of Trop Med Hyg 1993 ; 87 : 310
  • Catania S, Arassa C, Tzahtzoglou S, et al. Visceral leishmaniasis treated with liposomal amphotericin B. Pediatr In fee Dis J 1999 ; 18: 73-74
  • Davidson RM, Martino L, G radon i L, et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996 ; 22 : 938-943.
  • Smith OP, Harm IM, Cox H, Movelli V. Visceral leishmaniasis: rapid response to AmBisome treatment. Arc Dis Child 1995 ; 73 : 157-159.
  • Sunder S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial. Br Med J 2001 ; 323 :419- 422.

Year 2003, Volume: 16 Issue: 3, 211 - 213, 03.12.2016

Ayça Vitrinel Gülay Çiler Erdag Öznur Kılıç Tuba Giray Vural Kartal Şinasi Yaman Yasemin Akın

Abstract

References

  • I. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med tlyg 1992; 46 : 296-306.
  • Croft SL, Davidson RM, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother 1991 ; 28 : 111-118.
  • Meyrhoff A.U.S. Pood and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999 ;28 : 42-48.
  • Qradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995 ; 73 :191-197.
  • Thakur CP, Kumar M, Kumar P, Mishra BM, Pandey AK. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomized study. Br Med J 1988 ; 296 : 1557-1561.
  • Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez-Berestein Q. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 1986 ; 30 : 847-851.
  • Davidson RM, Croft SL, Scott AO, Maini M, Moody AH, Bryceson AOM. Liposomal amphotericin B in drug resistant visceral leishmaniasis. Lancet 1991 ; 337 : 1061- 1062
  • Davidson RM, Di Marti no L, Oradoni R, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi centre trial. Quart J Med 1994 ; 87 : 75-81.
  • Castagnola E, Davidson RM, Fiore P, et al. Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis. Trans Roy Soc Trop Med Hyg 1996 ; 90 : 31 7-318
  • Giacchino R, Giambartolome G, Tasso L, et al. Treatment with liposomal amphotericin B of a child affected with drug-resistant visceral leishmaniasis. Trans Roy Soc of Trop Med Hyg 1993 ; 87 : 310
  • Catania S, Arassa C, Tzahtzoglou S, et al. Visceral leishmaniasis treated with liposomal amphotericin B. Pediatr In fee Dis J 1999 ; 18: 73-74
  • Davidson RM, Martino L, G radon i L, et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996 ; 22 : 938-943.
  • Smith OP, Harm IM, Cox H, Movelli V. Visceral leishmaniasis: rapid response to AmBisome treatment. Arc Dis Child 1995 ; 73 : 157-159.
  • Sunder S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial. Br Med J 2001 ; 323 :419- 422.
There are 14 citations in total.

Details

Journal Section Case Reports
Authors

Ayça Vitrinel This is me

Gülay Çiler Erdag This is me

Öznur Kılıç This is me

Tuba Giray This is me

Vural Kartal This is me

Şinasi Yaman This is me

Yasemin Akın This is me

Publication Date December 3, 2016
Published in Issue Year 2003 Volume: 16 Issue: 3

Cite

APA Vitrinel, A., Çiler Erdag, G., Kılıç, Ö., Giray, T., et al. (2016). VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B. Marmara Medical Journal, 16(3), 211-213.
AMA Vitrinel A, Çiler Erdag G, Kılıç Ö, Giray T, Kartal V, Yaman Ş, Akın Y. VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B. Marmara Med J. March 2016;16(3):211-213.
Chicago Vitrinel, Ayça, Gülay Çiler Erdag, Öznur Kılıç, Tuba Giray, Vural Kartal, Şinasi Yaman, and Yasemin Akın. “VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B”. Marmara Medical Journal 16, no. 3 (March 2016): 211-13.
EndNote Vitrinel A, Çiler Erdag G, Kılıç Ö, Giray T, Kartal V, Yaman Ş, Akın Y (March 1, 2016) VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B. Marmara Medical Journal 16 3 211–213.
IEEE A. Vitrinel, G. Çiler Erdag, Ö. Kılıç, T. Giray, V. Kartal, Ş. Yaman, and Y. Akın, “VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B”, Marmara Med J, vol. 16, no. 3, pp. 211–213, 2016.
ISNAD Vitrinel, Ayça et al. “VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B”. Marmara Medical Journal 16/3 (March 2016), 211-213.
JAMA Vitrinel A, Çiler Erdag G, Kılıç Ö, Giray T, Kartal V, Yaman Ş, Akın Y. VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B. Marmara Med J. 2016;16:211–213.
MLA Vitrinel, Ayça et al. “VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B”. Marmara Medical Journal, vol. 16, no. 3, 2016, pp. 211-3.
Vancouver Vitrinel A, Çiler Erdag G, Kılıç Ö, Giray T, Kartal V, Yaman Ş, Akın Y. VISCERAL LEISHMANIASIS TREATED WITH LIPOSOMAL AMPHOTERICIN B. Marmara Med J. 2016;16(3):211-3.